Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more
Ascendis Pharma AS (ASND) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.434x
Based on the latest financial reports, Ascendis Pharma AS (ASND) has a cash flow conversion efficiency ratio of -0.434x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($70.67 Million) by net assets ($-162.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ascendis Pharma AS - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TransUnion
NYSE:TRU
|
0.070x |
|
Api Group Corp
NYSE:APG
|
0.071x |
|
Omega Healthcare Investors Inc
NYSE:OHI
|
0.042x |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
0.099x |
|
Carlisle Companies Incorporated
NYSE:CSL
|
0.214x |
|
NEXT plc
PINK:NXGPF
|
0.252x |
|
Repsol S.A
OTCQX:REPYF
|
0.059x |
|
Samsung Life
KO:032830
|
0.020x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-162.75 Million | $51.77 Million | -0.318x | -110.98% |
| 2024-12-31 | $-105.71 Million | $-306.20 Million | 2.897x | -9.70% |
| 2023-12-31 | $-145.70 Million | $-467.36 Million | 3.208x | +270.42% |
| 2022-12-31 | $263.35 Million | $-495.70 Million | -1.882x | -298.24% |
| 2021-12-31 | $883.63 Million | $-417.65 Million | -0.473x | -45.98% |
| 2020-12-31 | $838.71 Million | $-271.55 Million | -0.324x | -9.88% |
| 2019-12-31 | $597.11 Million | $-175.94 Million | -0.295x | +40.55% |
| 2018-12-31 | $280.05 Million | $-138.80 Million | -0.496x | +2.43% |
| 2017-12-31 | $187.21 Million | $-95.10 Million | -0.508x | -49.08% |
| 2016-12-31 | $176.61 Million | $-60.18 Million | -0.341x | +5.67% |
| 2015-12-31 | $120.33 Million | $-43.47 Million | -0.361x | +10.08% |
| 2014-12-31 | $45.81 Million | $-18.40 Million | -0.402x | -140.12% |
| 2013-12-31 | $6.30 Million | $6.31 Million | 1.001x | +338.99% |
| 2012-12-31 | $1.56 Million | $-652.00K | -0.419x | -- |